ROQUEFORT THERAPEUTICS PLC (LSE: ROQ) is a public company listed on the Main Market of the London stock exchange. Roquefort is a biotechnology company developing innovative cancer medicines in the high growth oncology market. Led by CEO AJAN REGINALD, Roquefort has portfolio of four pre-clinical anti-cancer drugs and 46 registered patents.
Roquefort Therapeutics (LSE: ROQ, OTCQB: ROQAF) (“Roquefort” or the “Company”) announces that two of its Midkine (MDK) antibody programs, ROQ-A1 and ROQ-A2, demonstrate in-vivo safety in
Roquefort Therapeutics PLC (LSE: ROQ) (Roquefort or the “Company”) is a public company listed on the Main Market of the London stock exchange. Roquefort is